Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company headquartered in Alpharetta, Georgia, with a portfolio focused on nutrition support and opioid-sparing pain management. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Avanos executes its strategy across its Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments.
Recent news releases highlight financial results, segment performance and portfolio changes. Avanos regularly reports quarterly results, detailing net sales, operating income and segment trends for SNS and PM&R, along with non-GAAP measures such as adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted EBITDA and free cash flow. These earnings updates often discuss demand in life-sustaining enteral feeding and neonate solutions, momentum in radiofrequency ablation (RFA) solutions and changes in surgical pain and recovery product volumes.
News coverage also includes strategic transactions and partnerships. Avanos has announced the divestiture of its Hyaluronic Acid product line, including TriVisc and GenVisc 850, to Channel-Markers Medical, and an agreement for WRS Group to acquire its US Game Ready orthopedic rental business while Avanos continues to manufacture and supply Game Ready systems and accessories under a long-term agreement. On the acquisition side, Avanos has reported the purchase of Nexus Medical, adding TKO anti-reflux needleless connector technology to its Specialty Nutrition Systems business.
In addition, Avanos issues updates on leadership changes, organizational restructuring and investor events, such as webcasts of earnings conference calls and presentations at healthcare conferences. Investors and observers can use this page to review how Avanos communicates its transformation progress, portfolio focus and financial performance over time.
Avanos Medical (NYSE: AVNS) reported its Q4 and full-year 2024 results, showing mixed performance. Q4 net sales reached $179.6 million, up 3.6% year-over-year, while full-year sales grew 2.2% to $687.8 million.
The company recorded a significant Q4 net loss of $397.0 million, largely due to a $436.7 million impairment charge on goodwill and intangible assets. Despite this, free cash flow improved to $82.9 million for 2024, compared to $14.6 million in 2023.
Q4 adjusted earnings per share increased to $0.43 from $0.36 year-over-year, while full-year adjusted EPS rose to $1.35 from $1.03. The company's net debt decreased to $27.0 million from $80.3 million previous year.
For 2025, Avanos projects net sales between $665-685 million and adjusted EPS of $1.05-1.25, reflecting challenging market conditions and currency headwinds.
Avanos Medical (NYSE: AVNS) has scheduled a conference call and webcast for Wednesday, Feb. 26 at 9 a.m. ET to discuss its fourth quarter and full year 2024 financial results. The company will release detailed financial results before the market opens on the same day. Michael Greiner, interim CEO, and Scott Galovan, senior vice president of strategy and corporate development, will host the call.
Participants can join the conference call through an automatic registration link or by dialing directly. A simultaneous webcast and related presentation will be available through the Investors section of the Avanos Medical website. The replay will be accessible for one week after the call.
Avanos Medical is a medical technology company based in Alpharetta, Georgia, focusing on medical device solutions for patient care, particularly in nutrition delivery and post-surgical recovery with reduced opioid use.
Avanos Medical (NYSE: AVNS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Michael Greiner, the company's interim chief executive officer, will deliver a presentation on Monday, January 13, at approximately 3:45 p.m. PST.
The presentation will be accessible via webcast through the Investors section of the Avanos Medical website, where it will also be archived for future reference.
Avanos Medical (NYSE: AVNS) has announced its participation in the Stifel 2024 Healthcare Conference. Michael Greiner, interim CEO, will engage in an analyst-led fireside chat at the Lotte New York Palace on Tuesday, Nov. 19 at 3:35 p.m. ET. The presentation will be accessible via webcast on the company's website's Investors section, where it will also be archived for future reference.
The Centers for Medicare and Medicaid Services (CMS) announced that Avanos Medical's ON-Q elastomeric infusion pump and ambIT disposable electronic infusion pump will receive separate Medicare payments under the NOPAIN Act starting January 1, 2025. This decision, part of the Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025, aims to enhance access to non-opioid pain management in HOPD and ASC settings. The NOPAIN Act, effective until December 31, 2027, provides additional Medicare reimbursement for qualifying non-opioid items to reduce opioid reliance. Both ON-Q and ambIT pumps will have unique HCPCS codes (C9804 and C9806) and a payment limit of up to $2,284.98 each. This move by CMS is a significant step in promoting safer pain management alternatives for Medicare beneficiaries.
Avanos Medical (NYSE: AVNS) has announced its participation in the UBS 2024 Healthcare Conference. Michael Greiner, the company's interim chief executive officer, will engage in a fireside chat on Tuesday, November 12 at approximately 2:45 p.m. Pacific Time. The presentation will be accessible via webcast through the Investors section of the Avanos Medical website, where it will also be archived for future reference.
Avanos Medical (NYSE: AVNS) has launched its new CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, expanding its Enteral Feeding portfolio. The system features a monofilament thread and is designed to reduce feeding tube dislodgement, which occurs in 40%-63% of tape-secured tubes. Key features include a yellow-tipped retrieval catheter with hollow tip, color-coded clips, printed centimeter markings, and an orange opening tool. The nasal bridle solution aims to improve tube survival rates and reduce complications associated with tube replacement.
Avanos Medical (NYSE: AVNS) reported Q3 2024 financial results and announced CEO Joe Woody's retirement. Total net sales were $170.4 million, down 0.5% year-over-year. The company reported net income of $5.9 million, compared to a net loss of $8.8 million in the prior year. Adjusted EBITDA increased to $30.6 million from $27.8 million. Despite transformation progress, the company fell short of mid-single-digit organic growth targets. The company updated its 2024 outlook, expecting revenue between $683-688 million and adjusted diluted EPS of $1.30-1.35.
Avanos Medical (NYSE: AVNS) has scheduled a conference call to discuss its third quarter 2024 financial results on Wednesday, October 30 at 9 a.m. ET. The company will release its financial results before market opening on the same day. The call will be led by CEO Joe Woody and CFO Michael Greiner.
Investors can join via phone (1-800-836-8184 for US callers) or through a simultaneous webcast on the company's investor relations website. A replay will be available from noon ET on October 30 for one week by calling 1-888-660-6345 (passcode: 38787#) or through the company's website.
Avanos Medical (NYSE: AVNS) has announced its participation in the CL King's 22nd Annual Best Ideas Conference 2024. Michael Greiner, the company's senior VP, CFO, and chief transformation officer, will engage in a fireside chat on September 16, 2024, at 9:30 a.m. Eastern Time. This virtual event provides an opportunity for investors to gain insights into Avanos Medical's strategies and performance.
The presentation will be accessible via webcast on the Investors section of the Avanos Medical website. For those unable to attend live, the webcast will be archived on the site for future viewing. This participation underscores Avanos Medical's commitment to investor relations and transparency in its operations.